Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

Research output: Contribution to journalReviewResearchpeer-review

  1. Limited inter- and intra-patient sequence diversity of the genetic lineage A human metapneumovirus fusion gene

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1

    Research output: Contribution to journalReviewResearchpeer-review

  • Ralf Bartenschlager
  • Thomas F Baumert
  • Jens Bukh
  • Michael Houghton
  • Stanley M Lemon
  • Brett D Lindenbach
  • Volker Lohmann
  • Darius Moradpour
  • Thomas Pietschmann
  • Charles M Rice
  • Robert Thimme
  • Takaji Wakita
View graph of relations

The development and clinical implementation of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C. Infection with any hepatitis C virus (HCV) genotype can now be eliminated in more than 95% of patients with short courses of all-oral, well-tolerated drugs, even in those with advanced liver disease and liver transplant recipients. DAAs have proven so successful that some now consider HCV amenable to eradication, and continued research on the virus of little remaining medical relevance. However, given 400,000 HCV-related deaths annually important challenges remain, including identifying those who are infected, providing access to treatment and reducing its costs. Moreover, HCV infection rarely induces sterilizing immunity, and those who have been cured with DAAs remain at risk for reinfection. Thus, it is very unlikely that global eradication and elimination of the cancer risk associated with HCV infection can be achieved without a vaccine, yet research in that direction receives little attention. Further, over the past two decades HCV research has spearheaded numerous fundamental discoveries in the fields of molecular and cell biology, immunology and microbiology. It will continue to do so, given the unique opportunities afforded by the reagents and knowledge base that have been generated in the development and clinical application of DAAs. Considering these critical challenges and new opportunities, we conclude that funding for HCV research must be sustained.

Original languageEnglish
JournalVirus Genes
Volume248
Pages (from-to)53-62
ISSN0920-8569
DOIs
Publication statusPublished - Mar 2018

    Research areas

  • Journal Article, Review

ID: 53366540